



***Investment Summit
October 19, 2010***

Presented by: Jenni Pilcher, CFO

Contact: jenni.pilcher@mesoblast.com

Company Snapshot

Regenerative Medicine Company

- ❑ *Head Office Melbourne*
- ❑ *Founder and CEO* → *Professor Silviu Itescu*
- ❑ *Acquired platform technology from Hansen Institute – Uni of SA*
- ❑ *Listed in Dec 2004 - ASX (“MSB”)*
- ❑ *Owns 38% of Angioblast Systems* → *Acquisition Pending*




Platform Technology

Adult Stem Cells = “MPCs” (Mesenchymal Precursor Cells)

- US Patents granted** → *isolation and expansion*
- +
- Non-immunogenic** → *unrelated donors*
- +
- Highly Expandable** → *batch-to-batch consistency*
- +
- Low Cost of Goods**
- =
- “Off-the-Shelf” products** → *pharma-style profit margins*



“Off-the-Shelf” Product Pipeline





Lead Product Targets

Lead Products	Target Disease	Latest Results/Stage of development	Phase III Start
Cord Blood Expansion	Bone Marrow Transplantation	25 patients transplanted = 80% 100 day survival with sustained engraftment; 38% for non-expanded cord blood (historical)	2011 <i>(orphan drug)</i>
Revascor™	Congestive Heart Failure	1 st cohort (Ph II) – improved heart muscle function at both 3 and 6 months	2012
NeoFuse™	Spinal Fusions (lumbar and cervical)	Mid Phase II – interim results expected Q1 2011	2012



Commercialisation

Lead Products	Patient Population	Alternative Treatments	MSB Competitive Advantage	Launch
Cord Blood Expansion for Bone Marrow Transplants	<ul style="list-style-type: none"> • 60k BMT procedures 	<ul style="list-style-type: none"> • BMT's from unrelated donors 	<ul style="list-style-type: none"> • Reduces GVHD • Broader market (across ethnic groups) 	2014
Congestive Heart Failure	<ul style="list-style-type: none"> • 5m existing + 600k diagnosed annually in the US alone 	<ul style="list-style-type: none"> • none 	<ul style="list-style-type: none"> • Improved heart muscle function, Quality of Life • Increased survival rates 	2015/16
Spinal Fusion	<ul style="list-style-type: none"> • 500k procedures annually in the US 	<ul style="list-style-type: none"> • Infuse (BMP2) • Autograft 	<ul style="list-style-type: none"> • Safer • no second surgery 	2015/16



Financials as at 30 June 2010

	<i>MSB</i>	<i>GROUP</i>
<i>Shares on Issue</i>	• 155m	• 228m to 241m
<i>Share Price</i>	• \$2.54	
<i>Market Capitalisation</i>	• \$393m	• \$580m to \$618m
<i>Cash Burn 2010</i>	• \$9m (annual)	• \$17m (annual)
<i>Cash Balance at 30 June</i>	• \$32m	• \$36m
<i>Funds Raised to Date</i>	• \$98m	• \$120m